Oncotelic Therapeutics, Inc. — Cash Flow Charts
52 quarters of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+73.9% +$712K
$-251K
Free Cash Flow↑+73.9% +$712K
$-251K
Investing Cash Flow
$6K
Financing Cash Flow↑+302.9% +$207K
$275K
Capex
$15K
Stock-Based Comp↓-40.5% -$188K
$276K
Debt Issued
$113K
Debt Repaid
$0
D&A↓-73.0% -$7K
$3K
SBC Allocated Expense↓-100.0% -$300K
$0
SBC Unrecognized Cost
$0